World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
63054
World Ranking
2704
National Ranking
1510

John V. Heymach publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John V. Heymach sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 920 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John V. Heymach D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John V. Heymach sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 128 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2017 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

John V. Heymach is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine with significant contributions to oncology and pulmonary and respiratory medicine. Their work also spans molecular biology and immunology, reflecting an interdisciplinary approach to cancer research.

The scientist's publication record includes numerous papers in key academic venues. These frequent publication venues feature:

  • Cancer Research
  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research

Heymach's main fields of study encompass medicine and biochemistry, genetics, and molecular biology. Their subfields provide further detail, highlighting oncology, pulmonary and respiratory medicine, molecular biology, cancer research, and immunology. These areas align with the primary topics covered in their research:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • HER2/EGFR in Cancer Research

Among recent papers attributed to Heymach are:

  • Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer, 2023, New England Journal of Medicine
  • Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities, 2021, Cancer Cell
  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021, Nature Medicine
  • Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations, 2020, New England Journal of Medicine
  • Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials, 2020, The Lancet Respiratory Medicine

The scientist has collaborated extensively with other researchers. Frequent co-authors include:

  • Don L. Gibbons
  • Jianjun Zhang
  • Xiuning Le
  • Ignacio I. Wistuba
  • Tina Cascone

John V. Heymach's contributions to the field have been recognized by several honors, including being named a Fellow of the American Association for the Advancement of Science (AAAS) in 2017 and membership in the Association of American Physicians.

Best Publications

  • Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

    Eric A. Collisson;Joshua D. Campbell;Angela N. Brooks;Angela N. Brooks;Alice H. Berger

  • Comprehensive genomic characterization of squamous cell lung cancers

    Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet

  • Molecular origins of cancer: Lung cancer

    Roy S. Herbst;John V. Heymach;Scott M. Lippman;Scott M. Lippman

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

    Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny

  • Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

    Daniel R. Gomez;Chad Tang;Jianjun Zhang;George R. Blumenschein

  • Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

    Daniel R Gomez;George R Blumenschein;J Jack Lee;Mike Hernandez

  • Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

    Limo Chen;Don Lynn Gibbons;Sangeeta Goswami;Maria Angelica Abdalla Cortez

  • The BATTLE Trial: Personalizing Therapy for Lung Cancer

    Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee

  • Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

    Jianjun Zhang;Junya Fujimoto;Jianhua Zhang;David C. Wedge

  • Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

    Charles M. Rudin;John T. Poirier;Lauren Averett Byers;Caroline Dive

  • PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Christopher Michael Gale;Eugene Lifshits

  • Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

    Ferdinandos Skoulidis;John V. Heymach

  • Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    Ferdinandos Skoulidis;Lauren A. Byers;Lixia Diao;Vassiliki A. Papadimitrakopoulou

  • Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

    Triparna Sen;B. Leticia Rodriguez;Limo Chen;Carminia Della Corte

  • Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

    C. Allison Stewart;Elizabeth M. Park;Lixia Diao

  • A pan-cancer proteomic perspective on The Cancer Genome Atlas

    Rehan Akbani;Patrick Kwok Shing Ng;Henrica M.J. Werner;Maria Shahmoradgoli

  • Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

    Nathan T. Ihle;Lauren Averett Byers;Edward S. Kim;Pierre Saintigny

  • Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

    Lauren Averett Byers;Jing Wang;Monique B. Nilsson;Junya Fujimoto

  • Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

    Jeffrey A. Engelman;Toru Mukohara;Kreshnik Zejnullahu;Eugene Lifshits

Frequent Co-Authors

Ignacio I. Wistuba
Ignacio I. Wistuba The University of Texas MD Anderson Cancer Center
Jing Wang
Jing Wang The University of Texas MD Anderson Cancer Center
Don L. Gibbons
Don L. Gibbons The University of Texas MD Anderson Cancer Center
Lixia Diao
Lixia Diao The University of Texas MD Anderson Cancer Center
Stephen G. Swisher
Stephen G. Swisher The University of Texas MD Anderson Cancer Center
J. Jack Lee
J. Jack Lee The University of Texas MD Anderson Cancer Center
Vassiliki A. Papadimitrakopoulou
Vassiliki A. Papadimitrakopoulou The University of Texas MD Anderson Cancer Center
Carmen Behrens
Carmen Behrens The University of Texas MD Anderson Cancer Center
John D. Minna
John D. Minna The University of Texas Southwestern Medical Center
Jack A. Roth
Jack A. Roth The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens up a range of related paths in the healthcare field—many of which can be accessed through flexible online programs. Students looking for alternatives to traditional medical school or seeking to supplement their education will find a variety of options tailored to different interests and needs.

For those aiming to enter nursing with fewer exam barriers, lpn to rn programs without teas test can be an efficient way to advance your qualifications. Aspiring nurse practitioners can also benefit from asn to np bridge programs, which help registered nurses take the next step toward advanced practice, all while studying online.

If you’re interested in the leadership side of healthcare, a healthcare administration degree online accredited provides business and managerial skills needed to run hospitals, clinics, and other health organizations.

There is also growing demand for nutrition and wellness experts. A bachelor's in nutrition online can prepare you for careers in public health, wellness coaching, or dietetics.

Best Scientists Citing John V. Heymach

Trending Scientists

Recently Published Articles